NCT01785056View on ClinicalTrials.gov

IVIG Treatment in Systemic Sclerosis

NAUnknownINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

January 31, 2018

Study Completion Date

January 31, 2019

Conditions
Systemic SclerosisDiffuse Scleroderma
Interventions
BIOLOGICAL

Privigen

Subjects will receive 2 g/kg/mo of Privigen® for 6 months if randomized to the treatment group.

Trial Locations (2)

20007

Georgetown University Hospital, Washington D.C.

21224

Johns Hopkins Hospital, Baltimore

Sponsors

Collaborators (1)

CSL Behring
All Listed Sponsors
collaborator

CSL Behring

INDUSTRY

lead

Georgetown University

OTHER

NCT01785056 - IVIG Treatment in Systemic Sclerosis | Biotech Hunter | Biotech Hunter